Array BioPharma to Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2018 on August 14, 2018


BOULDER, Colo., Aug. 7, 2018 /PRNewswire/ -- Array BioPharma, Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2018 and hold a conference call to discuss those results on Tuesday, August 14, 2018. Ron Squarer, Chief Executive Officer, will lead the call.

    Date:                                    Tuesday, August 14, 2018

    Time:                                    9:00 a.m. Eastern Time

    Toll-Free:                               (844) 464-3927

    Toll:                                    (765) 507-2598

    Pass Code:                                                 1766079

Webcast, including Replay and Conference Call Slides:

About Array BioPharma
Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets in the United States BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including selumetinib (partnered with AstraZeneca), larotrectinib (partnered with Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797 (being developed by Yarra Therapeutics, a wholly-owned subsidiary of Array), all of which are currently in registration trials. Ganovo® (danoprevir, partnered with Roche) was recently approved in China for the treatment of viral hepatitis C. For more information on Array, please visit or follow @arraybiopharma on Twitter and LinkedIn.

Array BioPharma
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate Communications
(303) 381-6600


View original content with multimedia:

SOURCE Array BioPharma Inc.

Company Codes: NASDAQ-NMS:ARRY

Back to news